ENTAのチャート
ENTAの企業情報
symbol | ENTA |
---|---|
会社名 | Enanta Pharmaceuticals Inc (エナンタ・ファ―マシュ―ティカルズ) |
分野(sector) | Health Care ヘルスケア |
産業(industry) | Major Pharmaceuticals |
業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連(Health Care) |
概要 | 事業概要 エナンタ・マシューティカル(Enanta Pharmaceuticals Inc.)は研究開発に集中するバイオテクノロジー企業である。同社は化学主導のアプローチと創薬機能を利用して、ウイルス感染および肝臓疾患の治療分野で小分子薬を作成する。同社の研究開発プログラムは非アルコール性脂肪性肝炎(NASH)/原発性胆道炎(PBC)、呼吸器合胞体ウイルス(RSV)及びB型肝炎ウイルス(HBV)を含む三つの疾患標的に集中する。同社はC型肝炎ウイルス(HCV)に対して直接作用抗ウイルス(DAA)阻害剤のクラスの一員としての新規プロテアーゼ阻害剤を発見した。これらのパリタプレビルおよびグレカププレビル(ABT-493)を含むプロテアーゼ阻害剤はAbbVie Inc. (AbbVie)と共同開発される。同社の製品候補はNASHおよびPBCに対するファルネソイドX受容体(FXR)アゴニスト製品候補及びRSVの臨床候補者であるEDP-938を含む。 エナンタ・ファ―マシュ―ティカルズは、米国のバイオ医薬品会社。感染症分野での小分子薬の作成に焦点を当て、研究開発に注力する。C型肝炎ウイルス(HCV)に対する阻害剤を発見、開発している。主要製品候補は、NS3プロテア―ゼの阻害剤「ABT-450」と多剤耐性菌感染症の治療に開発している二環式の抗生物質「Bicyclolides」である。 |
本社所在地 | 500 Arsenal Street Watertown MA 02472 USA |
代表者氏名 | Bruce L.A. Carter ブルースL.A.カーター |
代表者役職名 | Independent Chairman of the Board |
電話番号 | +1 617-607-0800 |
設立年月日 | 1995年 |
市場名 | NASDAQ National Market System |
ipoyear | 2013年 |
従業員数 | 89人 |
url | www.enanta.com |
nasdaq_url | https://www.nasdaq.com/symbol/enta |
adr_tso | ― |
EBITDA | EBITDA(百万ドル) 110.59200 |
終値(lastsale) | 77.48 |
時価総額(marketcap) | 1501370791.96 |
時価総額 | 時価総額(百万ドル) 1510.672 |
売上高 | 売上高(百万ドル) 215.34700 |
企業価値(EV) | 企業価値(EV)(百万ドル) 1239.288 |
当期純利益 | 当期純利益(百万ドル) 84.84400 |
決算概要 | 決算概要 BRIEF: For the nine months ended 30 June 2018 Enanta Pharmaceuticals Inc revenues increased from $26.9M to $139.4M. Net income before extraordinary items totaled $48.3M vs. loss of $18.8M. Revenues reflect Royalties increase from $26.9M to $124.4M Revenue increase from $0K to $15M. Net Income reflects Change in fair value of warrant liabilit increase from $45K (expense) to $41K (income). |
ENTAのテクニカル分析
ENTAのニュース
Enanta Pharmaceuticals to Present at Upcoming Investor Conferences 2021/03/02 12:01:00 Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at Upcoming Investor Conferences
Enanta Pharmaceuticals to Present at SVB Leerink 10th Annual Global Healthcare Conference 2021/02/18 21:02:00 Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at SVB Leerink 10th Annual Global Healthcare Conference
Oppenheimer Stick to Their Hold Rating for Enanta Pharmaceuticals By Investing.com 2021/02/09 04:15:00 Investing.com
Oppenheimer Stick to Their Hold Rating for Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. to Host Earnings Call 2021/02/08 19:30:00 Yahoo Finance
NEW YORK, NY / ACCESSWIRE / February 8, 2021 / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on February 8, 2021 at 4:30 PM Eastern Time.
Earnings Preview: Enanta Pharmaceuticals 2021/02/05 10:09:00 Benzinga
Enanta Pharmaceuticals (NASDAQ:ENTA) unveils its next round of earnings this Monday, February 08. Get prepared with Benzinga's ultimate preview for …
Enanta Pharmaceuticals to Present at Upcoming Investor Conferences 2021/03/02 12:01:00 Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at Upcoming Investor Conferences
Enanta Pharmaceuticals to Present at SVB Leerink 10th Annual Global Healthcare Conference 2021/02/18 21:02:00 Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at SVB Leerink 10th Annual Global Healthcare Conference
Oppenheimer Stick to Their Hold Rating for Enanta Pharmaceuticals By Investing.com 2021/02/09 04:15:00 Investing.com
Oppenheimer Stick to Their Hold Rating for Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. to Host Earnings Call 2021/02/08 19:30:00 Yahoo Finance
NEW YORK, NY / ACCESSWIRE / February 8, 2021 / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on February 8, 2021 at 4:30 PM Eastern Time.
Earnings Preview: Enanta Pharmaceuticals 2021/02/05 10:09:00 Benzinga
Enanta Pharmaceuticals (NASDAQ:ENTA) unveils its next round of earnings this Monday, February 08. Get prepared with Benzinga's ultimate preview for …
Enanta Pharmaceuticals Announces the Appointment of Tara L. Kieffer, Ph.D. as Senior Vice President, New Product Strategy and Development 2020/12/08 12:01:00 Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces the Appointment of Tara L. Kieffer, Ph.D. as Senior Vice President, New Product Strategy and Development
Enanta Pharma EPS misses by $0.52, misses on revenue (NASDAQ:ENTA) 2020/11/23 21:06:23 Seeking Alpha
Enanta Pharma (NASDAQ:ENTA): Q4 GAAP EPS of -$1.46 misses by $0.52. Revenue of $23.6M (-54.0% Y/Y) misses by $2.16M. 2021 Guidance: R&D Expense $145M-165M;
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020 2020/11/23 21:01:00 Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020